Multispecific CTL Generation Using Plasmid-Loaded Dendritic Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating multivirus-specific cytotoxic T lymphocytes (CTLs) are limited by the need for infectious virus material, high manufacturing costs, and prolonged culture times, especially when using small blood volumes, and similar challenges exist for generating tumor-associated antigen-specific CTLs due to the identification of appropriate target antigens and complex expansion procedures.
Innovation Solution
The use of dendritic cells nucleofected with DNA plasmids encoding immunodominant and subdominant viral antigens, combined with specific cytokines and specialized cell culture environments, allows for the rapid generation of multivirus-specific CTLs and multi-tumor-associated antigen-specific CTLs, utilizing plasmids or peptide libraries and gas permeable culture vessels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If infectious virus material is used for CTL generation, then CTL specificity against multiple viruses is achieved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent extracts the essential function of viral antigen presentation from the complex infectious virus material. Instead of using complete infectious viruses, the invention uses recombinant viral proteins and peptides that contain only the necessary antigenic determinants (epitopes) for CTL recognition, eliminating the complexity and safety issues associated with live viral materials while maintaining immunogenicity
Solution Approach 2:
The patent creates simplified copies of viral antigens through recombinant DNA technology. Viral proteins are expressed as recombinant antigens in cell lines or as synthetic peptides, which are functional copies that present the same epitopes as the native viral proteins without the complexity of complete viral particles, enabling CTL generation with reduced manufacturing complexity
2Quantity of substance
If conventional CTL expansion procedures are used, then adequate CTL numbers are produced, but culture time is prolonged
Solution Approach 1:
The patent applies preliminary action by pre-differentiating dendritic cells into mature antigen-presenting cells before antigen stimulation. The DCs are pre-loaded with multiple viral antigens through transfection or pulsing, and cytokine environments are pre-optimized to promote rapid CTL expansion. This preliminary preparation eliminates the need for sequential antigen presentations and reduces total culture time from weeks to days
Solution Approach 2:
The patent changes key cultural parameters including cytokine concentrations (IL-2, IL-7, IL-15), cell density ratios (DC to T cell ratios), and antigen presentation methods to create an optimized expansion environment. These parameter changes enable exponential CTL proliferation rates that achieve therapeutic doses in significantly reduced time compared to conventional protocols
3Object-affected harmful factors
If small blood volumes are used for CTL generation, then patient safety is improved, but CTL production efficiency decreases
Solution Approach 1:
The patent optimizes cultural parameters including higher cell density seeding, enhanced cytokine supplementation, and improved antigen presentation efficiency to maximize CTL expansion from limited starting material. These parameter changes enable sufficient CTL production from small blood volumes (e.g., 10-50 mL) that would be inadequate in conventional protocols, thereby enabling treatment of pediatric and debilitated patients
Solution Approach 2:
The patent performs preliminary enrichment of antigen-specific T cells from the small blood volume sample using tetramer staining or antigen-specific selection methods before expansion. This preliminary enrichment ensures that the limited starting material contains the highest possible concentration of relevant precursor cells, maximizing the efficiency of subsequent expansion from small volumes
4Adaptability or versatility
If multiple antigen presentations are performed sequentially, then broad epitope coverage is achieved, but manufacturing time is extended
Solution Approach 1:
The patent merges multiple antigen presentations into a single simultaneous stimulation event. Dendritic cells are transfected with or pulsed with multiple viral antigens (e.g., CMV, EBV, adenovirus, influenza) at the same time, creating a polyantigenic presentation environment that stimulates CTLs against multiple viruses concurrently. This eliminates the need for sequential antigen challenges and reduces manufacturing time while maintaining broad epitope coverage
Solution Approach 2:
The patent creates universal dendritic cell lines that can present multiple viral epitopes simultaneously through co-transfection with multiple antigen genes or use of combinatorial peptide libraries. These multi-functional DCs serve as a single platform for presenting diverse viral antigens, replacing the need for multiple specialized antigen presentation systems and enabling broad-spectrum CTL generation in a unified process
Data Source
AI summary
The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.